OptimizeRx Corp OPRX.OQ OPRX.O is expected to show a rise in quarterly revenue when it reports results on November 6 for the period ending September 30 2025
The Waltham Massachusetts-based company is expected to report a 11.8% increase in revenue to $23.833 million from $21.31 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
LSEG's mean analyst estimate for OptimizeRx Corp is for earnings of 4 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for OptimizeRx Corp is $19.00, about 2.3% below its last closing price of $19.44
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | 0.02 | 0.02 | 0.24 | Beat | 1,300.2 |
Mar. 31 2025 | -0.13 | -0.12 | 0.08 | Beat | 166.7 |
Dec. 31 2024 | 0.28 | 0.27 | 0.30 | Beat | 10.6 |
Sep. 30 2024 | 0.06 | 0.06 | 0.12 | Beat | 94.5 |
Jun. 30 2024 | -0.06 | -0.06 | 0.02 | Beat | 131.3 |
Mar. 31 2024 | -0.12 | -0.13 | -0.11 | Beat | 13.7 |
Dec. 31 2023 | 0.33 | 0.32 | 0.26 | Missed | -19.5 |
Sep. 30 2023 | 0.03 | 0.03 | 0.09 | Beat | 260 |
This summary was machine generated November 4 at 22:33 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments